Italy possesses one of the most comprehensive Newborn Screening (NBS) programs in Europe, governed by Law 167/2016. This public health initiative mandates the screening of all newborns for nearly 50 metabolic, endocrine, and genetic conditions. The testing is performed using a "dried blood spot" collected from the infant's heel within the first 48 to 72 hours of life.
By 2026, the program has expanded to include pilot projects for high-impact genetic disorders such as Metachromatic Leukodystrophy (MLD) and Spinal Muscular Atrophy (SMA). The Italian model is particularly effective because it links the diagnostic laboratory directly to clinical "confirmation centers" and specialized treatment units. This ensures that a positive screening result leads to immediate intervention—such as enzyme replacement therapy or gene therapy—before irreversible physiological damage occurs. The success of this program is measured by the "diagnostic odyssey" reduction, moving the time to diagnosis from years to days for thousands of Italian families.